Advertisement
In a communication to all states and UT drugs controllers cum licensing authorities, the Drugs Controller Genral of India (DCGI) stated that the decision was taken in view of the opinion that “blood is not for sale”.
Referring to the 62nd meeting of the Drugs Consultative Committee held on September 26, 2023, the DCGI in the letter on December 26 said, “It was recommended with respect of agenda No. 18 of ATR point 3, for overcharging of blood, it was opined that blood is not for sale, it is only for supply and only processing cost may be charged by the blood centre.” The revised guidelines stipulate that only processing fees can be charged for blood or blood components which ranges between Rs 250 to 1,550 for blood or blood components.
The DCGI has asked states and UT drug controllers to direct all blood centres under their jurisdiction to adhere to the revised guidelines.
Related Articles
Advertisement